Cdc7-IN-6 (compound I-D) is a potent Cdc7 kinase inhibitor (IC50=4 nM), extracted from patent WO2019165473A1, compound I- D, has anti-tumor activity.

Product information

CAS Number: 1402057-88-8

Molecular Weight: 465.43

Formula: C21H22F3N5O4

Chemical Name: ethyl 4-hydroxy-5-{[(3Z)-3H-pyrrolo[2,3-b]pyridin-3-ylidene]methyl}-2-{[4-(2,2,2-trifluoroethyl)piperazin-1-yl]amino}furan-3-carboxylate

Smiles: CCOC(=O)C1C(O)=C(/C=C2\C=NC3=NC=CC=C\23)OC=1NN1CCN(CC(F)(F)F)CC1

InChiKey: HFBNZZVVRMLDJO-JLHYYAGUSA-N

InChi: InChI=1S/C21H22F3N5O4/c1-2-32-20(31)16-17(30)15(10-13-11-26-18-14(13)4-3-5-25-18)33-19(16)27-29-8-6-28(7-9-29)12-21(22,23)24/h3-5,10-11,27,30H,2,6-9,12H2,1H3/b13-10+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Cdc7-IN-6 demonstrates potent inhibitory activity (IC50<3 µΜ) in a range of solid tumor cell lines, including those of bladder (5673, RT1 12/84), sarcoma (143B, CADO-ES1, RD-ES, A673), colon and cecum (Colo-205, DLD-l, LS1034, SK-CO-l, SNU-C1), renal (U0.31), head-and-neck (CNE-2Z, RPMI-2650), melanoma (A2058, A875), and gastric (HGC-27) lineages.

Products are for research use only. Not for human use.